Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9395712rdf:typepubmed:Citationlld:pubmed
pubmed-article:9395712lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:9395712lifeskim:mentionsumls-concept:C0060623lld:lifeskim
pubmed-article:9395712pubmed:dateCreated1998-1-14lld:pubmed
pubmed-article:9395712pubmed:abstractTextFollistatin (FS), a specific binding protein for activin, neutralizes the diverse actions of activin by forming an inactive complex with activin. FS is a monomer derived from two polypeptide core sequences of 288 (FS-288) and 315 (FS-315) amino acids originated from alternatively spliced mRNA. We purified six molecular forms of FS from porcine ovaries. Their structural differences were caused by truncation of the COOH-terminal region and/or the presence of carbohydrate chains, resulting in the formation of FS-288, FS-315 and FS composed of 303 amino acids (FS-303) in various forms of glycosylation on the two potential Asn-linked glycosylation sites. All six molecular species have almost the same activin binding activity (Kd = 540-680 pM). By contrast, the COOH-terminal truncated form, FS-288, showed much higher affinity for heparan sulfate proteoglycans of the cell surface than FS-303, whereas the intact form of FS, FS-315, had no affinity. Furthermore, FS-288 more effectively blocked the suppression of follicle-stimulating hormone (FSH) secretion from rat pituitary cells by activin. This implies that activin binds to the cell surface through FS-288 which adheres to the cell surface. To clarify the physiological role of cell-associated FS, we then investigated the binding of activin to cell-associated FS and the fate of cell surface-bound activin and FS using primary cultured rat pituitary and ovarian granuloma cells. When the cells were incubated with 125I-activin A in the presence of FS-288 or 315, the binding of activin A to the cell surface was promoted much more markedly by FS-288 than by FS-315. The amounts of radioactivity recovered in trichloroacetic acid-soluble fractions (degraded activin) from the incubation medium were greatly increased by the addition of FS-288. This increase was abolished by heparan sulfate, monensin (an endocytosis inhibitor), chloroquine (a lysosome function inhibitor) and several lysosomal enzyme inhibitors. These results suggest that cell-associated FS-288 accelerates the internalization of activin into the cells, leading to its degradation by lysosomal enzymes, and that cell surface-associated FS therefore plays a role in the clearance system of activin.lld:pubmed
pubmed-article:9395712pubmed:languageenglld:pubmed
pubmed-article:9395712pubmed:citationSubsetIMlld:pubmed
pubmed-article:9395712pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9395712pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9395712pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9395712pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9395712pubmed:statusMEDLINElld:pubmed
pubmed-article:9395712pubmed:authorpubmed-author:NakamuraTTlld:pubmed
pubmed-article:9395712pubmed:authorpubmed-author:ShojiHHlld:pubmed
pubmed-article:9395712pubmed:authorpubmed-author:HashimotoOOlld:pubmed
pubmed-article:9395712pubmed:authorpubmed-author:SuginoHHlld:pubmed
pubmed-article:9395712pubmed:authorpubmed-author:SuginoKKlld:pubmed
pubmed-article:9395712pubmed:ownerNLMlld:pubmed
pubmed-article:9395712pubmed:authorsCompleteYlld:pubmed
pubmed-article:9395712pubmed:pagination1-14lld:pubmed
pubmed-article:9395712pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:meshHeadingpubmed-meshheading:9395712-...lld:pubmed
pubmed-article:9395712pubmed:articleTitleFollistatin and its role as an activin-binding protein.lld:pubmed
pubmed-article:9395712pubmed:affiliationDivision of Molecular Cytology, University of Tokushima, Japan.lld:pubmed
pubmed-article:9395712pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9395712pubmed:publicationTypeReviewlld:pubmed
pubmed-article:9395712pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9395712lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9395712lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9395712lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9395712lld:pubmed